14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
COCP vs PRPO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Precipio, Inc. (PRPO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas PRPO carries 32.2/100 (SELL) at $20.39 (15.4x Forward P/E, -5.3% operating margin).
Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. PRPO 32.2/100 SELL), PRPO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-5.3% vs. -3063.6% operating margin) and revenue trajectory (+8.3% vs. +26.9% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COCP vs PRPO. Trailing 12-month operating profitability (COCP -3063.6% vs PRPO -5.3%) and valuation multiples (COCP N/M vs PRPO 15.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Diagnostics & Research value chain with $40.2M market capitalization and -5.3% operating margin.
OpEx & R&D Reinvestment49.9% of Rev ($14M)
90D Engineering Disclosures0 Published
Investor FAQ COCP vs PRPO Key Questions & Quantitative Answers
As of Nov 16, 2026, Precipio, Inc. (PRPO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas PRPO carries 32.2/100 (SELL) at $20.39 (15.4x Forward P/E, -5.3% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. PRPO 32.2/100 SELL), PRPO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-5.3% vs. -3063.6% operating margin) and revenue trajectory (+8.3% vs. +26.9% YoY).
PRPO leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with PRPO at +8.3% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (44.6% gross margin, -5.3% operating margin). On trailing 12-month operating scale, COCP generates $330,000 in USD-normalized revenue versus $28M for PRPO. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus 49.9% of Rev ($14M) (0 disclosures) for PRPO.
PRPO screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin), whereas PRPO trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-0.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus PRPO (-8.0% ROE) capital efficiency.
In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk). By comparison, PRPO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 95% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.